RE:RE:RE:RE:RE:mdjbrown...agree, be it today or 30 years ago on a posting When speaking to patent challenges like with the ANDA epidiolex generic, yes it could be dragged out...however we also have clients who've applied for an NDA, and 505b2, it appears some can't grasp the concept of API supply and the fact LABS isn't involved in most clinical trials, instead LABS involvement lies with the API supply for commercialization once approved...Someone here claimed the other week the NDA and 505b2 claim was a lie because they cannot find a stage three trial attached to medipharm.......they don't understand the concept of API supply and the fact they don't need to be involved in any clinical trial to be a supplier of active pharmaceutical for such drug once approved...please familiarize yourself with the FDA drug applications and process, you only apply when your data is complete including clinical trials....lemon..:this is all fact based..all true..unless you believe LABS is defrauding its investors by issueing false claims on its investors deck....don't come here and claim we've blown the pharma prospect outta proportion before doing some DD which you clearly haven't....stay over at yahoo..